Track topics on Twitter Track topics that are important to you
JERUSALEM--(BUSINESS WIRE)--Jan. 18, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the U.S. Food and Drug Administration (FDA) approved Vantrela ER (hydrocodone bita...
Brian BerkIt is indicated for the relief of moderate to moderately severe pain. read more
Brian BerkThe solutions are indicated for the symptomatic relief of cough in adults and children 6 years of age and older. read more
The AA-rated generic version of Mikart's Hydrocodone Bitartrate and Acetaminophen tablets USP, 5 mg/300 mg, 7.5 mg/300 mg and -More-
The US Food and Drug Administration has approved Vantrela ER (hydrocodone bitartrate) extended-release…
Lupin's abbreviated new drug application for hydrocodone bitartrate and homatropine methylbromide oral solution has been appr -More-
Teva Pharmaceutical Industries' Vantrela ER, or hydrocodone bitartrate extended-release tablet, has been approved by the FDA -More-
Hydrocodone bitartrate extended-release (Hysingla(®) ER; referred to hereafter as hydrocodone ER) was the first single-entity hydrocodone formulation recognized by the US FDA as having abuse-deterren...
A once-daily, extended-release hydrocodone bitartrate tablet with abuse-deterrent properties (Hysingla ER [HYD]) is available for the treatment of chronic pain in appropriate patients. This study e...
This study evaluated the safety and effectiveness of a once-daily, single-entity, extended-release hydrocodone bitartrate (HYD) among patients with chronic noncancer and non-neuropathic pain who requi...
Use/misuse of the opioid combination hydrocodone-acetaminophen has been associated with permanent hearing loss. Although reports have been rare, this potential effect can have significant detrimental ...
In 2012, hydrocodone combination products (HCPs) were the most prescribed medications in the United States. Under the Controlled Substance Act of 1970, hydrocodone alone was classified as a Schedule I...